MedTrace Logo

GzmB-PET/CT to Evaluate Neoadjuvant Therapy Efficacy in Breast Cancer

NCT06725940 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-12-10

No results posted yet for this study

Summary

To explore the efficacy of 68Ga-GZMB PET/CT in assessing the response to neoadjuvant therapy for breast cancer, and to investigate the optimal SUVmax threshold of 68Ga-GZMB PET/CT for predicting pathological complete response (pCR), aiming to provide a new and effective means for accurately and non-invasively evaluating the efficacy of neoadjuvant therapy.

Conditions

  • Breast Cancer Invasive

Interventions

DEVICE

68Ga-GZMB PET/CT

68Ga-GZMB PET/CT

Sponsors & Collaborators

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Xiaosong Chen · Shanghai Jiaotong University School of Medicine affiliated Ruijin Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2025-11-01
Completion
2025-11-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06725940 on ClinicalTrials.gov